| Trial ID: | L0051 |
| Source ID: | NCT02684591
|
| Associated Drug: |
Aramchol
|
| Title: |
Aramchol for HIV-associated Nonalcoholic Fatty Liver Disease and Lipodystrophy
|
| Acronym: |
ARRIVE
|
| Status: |
Completed
|
| Study Results: |
Has Results
|
| Results: |
https://ClinicalTrials.gov/show/NCT02684591/results
|
| Conditions: |
Nonalcoholic Fatty Liver Disease|HIV
|
| Interventions: |
Drug: Aramchol|Drug: Placebo
|
| Outcome Measures: |
Efficacy of Aramchol 600 mg vs. Placebo in Improving Hepatic Steatosis Assessed by Magnetic Resonance Imaging in Patients With HIV-associated NAFLD|Serum Alanine Aminotransferase (ALT)
|
| Sponsor/Collaborators: |
University of California, San Diego
|
| Gender: |
All
|
| Age: |
18 Years and older ?? (Adult, Older Adult)
|
| Phases: |
Phase 2
|
| Enrollment: |
50
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
|
| Start Date: |
January 2016
|
| Completion Date: |
February 2018
|
| Results First Posted: |
August 21, 2019
|
| Last Update Posted: |
July 17, 2020
|
| Locations: |
University of California, San Diego, San Diego, California, United States
|
| URL: |
https://ClinicalTrials.gov/show/NCT02684591
|
